NCT01376323 - A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 13, 2011

Primary Completion Date

September 16, 2012

Study Completion Date

September 17, 2012

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

GSK256073 1mg

GSK256073 1mg capsule

DRUG

GSK256073 5mg

GSK256073 5mg capsule

DRUG

GSK256073 10mg

GSK256073 10mg capsule

DRUG

GSK256073 25mg

GSK256073 25mg capsule

DRUG

Placebo

placebo capsule

DRUG

Sitagliptin 100mg

Sitagliptin 100mg capsule

Trial Locations (15)

18004

GSK Investigational Site, Granada

28046

GSK Investigational Site, Madrid

33025

GSK Investigational Site, Miramar

33169

GSK Investigational Site, Miami

35046

GSK Investigational Site, Rennes

36207

GSK Investigational Site, Anniston

44093

GSK Investigational Site, Nantes

69495

GSK Investigational Site, Pierre-Bénite

92502

GSK Investigational Site, Rueil-Malmaison

03114

GSK Investigational Site, Alicante

08916

GSK Investigational Site, Badalona

EH4 2XU

GSK Investigational Site, Edinburgh

CB2 0GG

GSK Investigational Site, Cambridge

CV2 2DX

GSK Investigational Site, Coventry

NE1 4LP

GSK Investigational Site, Newcastle upon Tyne